#1 Clinical Trials Search in Europe

Sodium Iodide (131I)

This article explores the use of Sodium Iodide (131I) in clinical trials for treating various thyroid conditions. Sodium Iodide (131I) is a radioactive form of iodine used in medical treatments, particularly for thyroid-related disorders. The trials discussed here focus on its application in differentiated thyroid cancer and Graves’ disease with associated orbitopathy. These studies aim to optimize treatment strategies, personalize therapy, and compare outcomes with other treatment methods.

Table of Contents

What is Sodium Iodide (131I)?

Sodium Iodide (131I), also known as radioactive iodine or RAI, is a radioactive form of iodine used in medical treatments[1]. It is primarily used to treat certain thyroid conditions and thyroid cancer. This medication is available in different forms, including capsules and solutions, and is administered orally[2].

Medical Conditions Treated

Sodium Iodide (131I) is used to treat several thyroid-related conditions:

  • Differentiated Thyroid Cancer (DTC): This includes papillary and follicular thyroid cancers[1].
  • Graves’ Disease: An autoimmune disorder causing hyperthyroidism (overactive thyroid)[3].
  • Graves’ Orbitopathy (GO): An eye condition associated with Graves’ disease[3].
  • Metastatic Thyroid Cancer: Cancer that has spread beyond the thyroid gland[2].

How It Works

Sodium Iodide (131I) works by targeting thyroid cells, including cancerous ones. The thyroid gland naturally absorbs iodine, and when radioactive iodine is introduced, it is taken up by thyroid cells. The radiation then destroys these cells, effectively treating thyroid cancer or reducing an overactive thyroid[1][2].

Administration and Dosage

Sodium Iodide (131I) is typically administered orally in the form of capsules or solution. The dosage varies depending on the condition being treated and individual patient factors. For thyroid cancer treatment, doses can range from 3.7 GBq (gigabecquerels) to 7.4 GBq[1]. In some cases, personalized dosing based on pre-treatment imaging may be used to optimize treatment[2].

Effectiveness

The effectiveness of Sodium Iodide (131I) treatment can vary depending on the condition:

  • For thyroid cancer, it has been shown to be effective in destroying remaining thyroid tissue after surgery and treating metastatic disease[1].
  • In Graves’ disease, it can effectively reduce thyroid function to manage hyperthyroidism[3].

Ongoing research is exploring ways to optimize treatment effectiveness, such as using pre-treatment imaging to guide dosing[2].

Side Effects and Precautions

While Sodium Iodide (131I) is generally well-tolerated, it can cause side effects and requires certain precautions:

  • Short-term side effects may include nausea, dry mouth, and changes in taste[1].
  • Long-term effects can include an increased risk of developing other cancers, though this risk is generally low[1].
  • Precautions: Patients should avoid close contact with others, especially pregnant women and young children, for a period after treatment due to radiation exposure[1].
  • Women who are pregnant or breastfeeding should not receive this treatment[3].

Ongoing Research

Several clinical trials are currently exploring ways to improve the use of Sodium Iodide (131I) in treating thyroid conditions:

  • A study is comparing systematic radioiodine administration versus a guided approach based on post-operative evaluation in intermediate-risk thyroid cancer patients[1].
  • Another trial is investigating personalized therapy for metastatic thyroid cancer using pre-treatment imaging to optimize dosing[2].
  • Research is also being conducted to compare the effects of radioiodine treatment versus antithyroid drugs in patients with Graves’ disease and active Graves’ orbitopathy[3].

These studies aim to improve treatment outcomes, minimize side effects, and personalize therapy for individual patients.

Aspect Details
Primary Conditions Studied Differentiated Thyroid Cancer, Graves’ Disease with Orbitopathy
Main Objectives Optimize radioiodine treatment, compare treatment strategies, personalize therapy
Administration Method Oral capsules
Dosage Range Varies by trial; up to 3.7 GBq for thyroid cancer, 15 mCi for Graves’ disease
Key Outcome Measures Response rates, toxicity, quality of life, cost-effectiveness
Innovative Approaches Personalized dosimetry using 124I-PET/CT, comparison with conservative treatments
Patient Populations Adults with specific thyroid conditions, varying inclusion/exclusion criteria
Follow-up Duration Ranges from 24 weeks to 5 years, depending on the trial

FAQ

  • What is Sodium Iodide (131I) used for in these clinical trials? Sodium Iodide (131I) is being studied for treating differentiated thyroid cancer and hyperthyroidism associated with Graves' disease. It's used as a radioactive therapy to target and destroy thyroid tissue.
  • How is Sodium Iodide (131I) administered to patients? In these trials, Sodium Iodide (131I) is administered orally, typically in the form of capsules. The dose is carefully calculated based on the patient's condition and the specific trial protocol.
  • What are the potential benefits of using Sodium Iodide (131I) in thyroid cancer treatment? Sodium Iodide (131I) can potentially eliminate remaining thyroid tissue after surgery and target thyroid cancer cells that have spread to other parts of the body. It offers a targeted approach to treating thyroid cancer.
  • Are there any risks or side effects associated with Sodium Iodide (131I) treatment? While not explicitly stated in the trial information, radioiodine therapy can have side effects such as temporary neck swelling, nausea, and dry mouth. Long-term risks may include an increased risk of other cancers, but this is generally low.
  • How do researchers determine the appropriate dose of Sodium Iodide (131I) for each patient? In some trials, researchers use pre-treatment dosimetry based on 124I-PET/CT scans to personalize the dose. This approach aims to optimize the treatment by tailoring the amount of radioiodine to each patient's specific needs.

Ongoing Clinical Trials on Sodium Iodide (131I)

  • Study Comparing Two Treatment Strategies for Intermediate-Risk Thyroid Cancer Using Sodium Iodide (131I) in Patients with Post-Surgery Evaluation

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Evaluation of personalized Iodine-131 therapy using PET imaging in patients with metastatic thyroid cancer

    Recruiting

    2 1 1 1
    Investigated drugs:
    Italy

  • Study Comparing Radiofrequency Ablation and Sodium Iodide (131I) for Treating Hyperthyroidism in Patients with Overactive Thyroid Nodules

    Not yet recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

  • Study Comparing Thiamazole and Sodium Iodide (131I) for Treating Hyperthyroidism in Patients with Graves’ Disease and Active Graves’ Orbitopathy

    Not yet recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy

Glossary

  • Differentiated Thyroid Cancer (DTC): A type of thyroid cancer that develops from follicular cells in the thyroid gland. It includes papillary and follicular thyroid cancers, which generally have a good prognosis.
  • Radioiodine (RAI): A radioactive form of iodine, typically Iodine-131, used to treat thyroid conditions. It's taken up by thyroid cells, allowing targeted treatment of thyroid tissue.
  • Thyroglobulin (Tg): A protein produced by the thyroid gland. Its levels in the blood can be used to monitor for recurrence of thyroid cancer after treatment.
  • PET/CT: Positron Emission Tomography/Computed Tomography, an imaging technique that combines PET and CT scans to provide detailed images of the body's structures and metabolic activity.
  • Graves' Disease: An autoimmune disorder that leads to overproduction of thyroid hormones (hyperthyroidism). It can also affect the eyes, causing a condition called Graves' orbitopathy.
  • Orbitopathy: A condition affecting the eyes and surrounding tissues, often associated with thyroid disorders, particularly Graves' disease.
  • Dosimetry: The measurement and calculation of radiation dose in tissue. In these trials, it's used to determine the optimal amount of radioiodine for each patient.
  • Euthyroid: A state where thyroid hormone levels are within the normal range.
  • Antithyroid Drugs (ATDs): Medications used to treat hyperthyroidism by reducing the production of thyroid hormones.
  • Clinical Activity Score (CAS): A scoring system used to assess the activity of Graves' orbitopathy, considering factors like eye redness, swelling, and pain.

References

  1. http://clinicaltrials.eu/trial/study-comparing-two-treatment-strategies-for-intermediate-risk-thyroid-cancer-using-sodium-iodide-131i-in-patients-with-post-surgery-evaluation/
  2. http://clinicaltrials.eu/trial/study-on-personalized-treatment-for-metastatic-thyroid-cancer-using-sodium-iodide-131i-for-patients-with-soft-tissue-and-bone-metastases/
  3. http://clinicaltrials.eu/trial/study-comparing-thiamazole-and-sodium-iodide-131i-for-treating-hyperthyroidism-in-patients-with-graves-disease-and-active-graves-orbitopathy/